XML 46 R31.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaborative Research, Development and License Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2015
Astra Zeneca |
Summary of Revenue Recognized under Various Agreements | The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):
|  | Year ended December 31, |
|  | 2015 |  |  | 2014 |  |  | 2013 |
Initial payment |  | $ | 238 |  |  | $ | 681 |  |  | $ | 720 |
Subsequent payment |  |  | 892 |  |  |  | 2,554 |  |  |  | - |
Performance of research activities |  |  | 1,635 |  |  |  | 2,174 |  |  |  | 2,507 |
Total |  | $ | 2,765 |  |  | $ | 5,409 |  |  | $ | 3,227 |
Glaxo Smith Kline |
Summary of Revenue Recognized under Various Agreements | The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our consolidated statements of operations (in thousands):
|  | Year ended December 31, |
|  | 2015 |  |  | 2014 |  |  | 2013 |
Initial payment |  | $ | - |  |  | $ | 2,524 |  |  | $ | 1,702 |
Total |  | $ | - |  |  | $ | 2,524 |  |  | $ | 1,702 |
National Institutes of Health |
Summary of Revenue Recognized under Various Agreements | The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our consolidated statements of operations (in thousands):
|  | Year ended December 31, |
|  | 2015 |  |  | 2014 |  |  | 2013 |
NIAID contracts |  | $ | - |  |  | $ | 2,095 |  |  | $ | 4,103 |
All other NIH contracts |  |  | 683 |  |  |  | 593 |  |  |  | 1,035 |
Total grant revenue |  | $ | 683 |  |  | $ | 2,688 |  |  | $ | 5,138 |

X
- Definition Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51671369&loc=d3e50766-111635 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635 + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |